AgeX Therapeutics acquires technology to regulate immune tolerance
AgeX Therapeutics, a subsidiary of BioTime, announced it has acquired certain patents and patent applications from Escape Therapeutics relating primarily to the use of the HLA-G gene to suppress rejection of transplanted cells and tissues. August 16, 2018